Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of pediatric acute lymphoblastic leukemia.
Lead Product(s): SLS009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Details:
SLS-001 (galinpepimut-S) is a WT1 inhibitor vaccine candidate which is being developed in combination with sargramostim for the treatment of acute myeloid leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Details:
SLS-001 (galinpepimut-S) is a WT1 inhibitor vaccine candidate which is being developed in combination with sargramostim for the treatment of acute myeloid leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): SLS009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2024
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): SLS009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
SLS-001 (galinpepimut-S) is a WT1 inhibitor vaccine candidate which is being developed in combination with sargramostim for the treatment of acute myeloid leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): SLS009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The net proceeds will be used in the clinical development of SLS-001 (galinpepimut-S) in combination with Sargramostim. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 19, 2024
Details:
The net proceeds will be used in the clinical development of SLS-001 (galinpepimut-S) in combination with Sargramostim. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 15, 2024
Details:
GFH009 (SLS009) is a novel and highly selective CDK9 inhibitor, which is under phase 1/2 clinical development for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML).
Lead Product(s): SLS009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024